BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32215944)

  • 1. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway.
    Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H
    Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of DUXAP10 inhibits proliferation and promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR signaling pathway.
    Lv XY; Ma L; Chen JF; Yu R; Li Y; Yan ZJ; Cheng Y; Ma Q
    Int J Oncol; 2018 Jan; 52(1):288-294. PubMed ID: 29115412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma.
    Zhou GK; Zhang GY; Yuan ZN; Pei R; Liu DM
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8772-8780. PubMed ID: 30575918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
    Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
    Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
    Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
    Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway.
    Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X
    J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.
    Chen Y; Hao SA; Jiang Y; Gao B; Tian WG; Zhang S; Guo LJ; Wang LL; Luo DL
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7989-7999. PubMed ID: 31599424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 10. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway.
    Chen L; Zhuo D; Yuan H
    Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
    Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT
    Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
    Wu YC; Li SY; Jia YF
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-17-5p knockdown inhibits proliferation, autophagy and promotes apoptosis in thyroid cancer via targeting PTEN.
    Shi YP; Liu GL; Li S; Liu XL
    Neoplasma; 2020 Mar; 67(2):249-258. PubMed ID: 31973533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
    Gao H; Sun X; Wang H; Zheng Y
    Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPHA2 Promotes the Invasion and Migration of Human Tongue Squamous Cell Carcinoma Cal-27 Cells by Enhancing AKT/mTOR Signaling Pathway.
    Wang F; Zhang H; Cheng Z
    Biomed Res Int; 2021; 2021():4219690. PubMed ID: 33834064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma.
    Sun YH; Liu ZF; Yang BB; Yu B
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8429-8439. PubMed ID: 31646573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.